• 作者：A. Courties^a ; O. Lidove^a ; ^{olidove@hopital-dcss.org" class="auth_mail} ; T. Maisonobe^b ; A. Rigolet^c ; A. Hermet^a ; P. Girard^d ; J.-M. Ziza^a
• 关键词：Cancer ; Syndrome des antisynthé ; tases ; Anticorps anti-Ro-52
• 刊名：La Revue de Medecine Interne
• 出版年：April, 2014
• 年：2014
• 卷：35
• 期：4
• 页码：271-273
• 全文大小：584 K

Introduction

Dermatomyositis and polymyositis are sometimes associated with neoplasia. Conversely, a link between antisynthetase syndrome and neoplasia has not been clearly demonstrated.

Case report

We report a 54-year-old smoker male patient who presented with an antisynthetase syndrome with anti-Jo1 and anti-Ro-52 antibodies. An adenocarcinoma of the lung was diagnosed at the same time.

Conclusion

Two recent studies showed that patients with an antisynthetase syndrome associated with anti-Jo1 antibodies have more severe prognosis than antisynthetase syndrome associated with other antibodies (i.e. PL7/PL12). The risk of cancer occurrence seems to be increased when the anti-Jo1 antisynthetase syndrome is associated with anti-Ro-52 antibodies. To date, there is no demonstrated association between antisynthetase syndrome and neoplasia.